A[k44’ hon7’32go Dikos Ndtsa1’7-`19 Bi deezla’ Bi N1bin Azee’ 

bid7d0[ nihii Naalkah gi t’11’ 1yis77 Baa hasti’ g hoo’a’ go tsx88[ 

go a N1bin 1lneh7g77 chii doo’i[ gi Bee Haz1anii Bee l32 doo.

FDA

(Chiy11n d00’ Azee’ Baa 

hasti’ii Bi Bee Haz1anii 

Bee Bik’i’ad4st’99’j7) Na[nih 

da; ats’7s b22h da hwii doo’

a[gi 11j7 deezl1 / ba’1t’e’

adaat’47 N1bin bich’23h chii 

doo’i[ii Ni b44 hees k11’ii.

www.FDA.gov/COVID19vaccines

#FDAVaccineFacts

1FDA {a’go Dikos Ndts11’7 19 bi 

deezla’ bi N1bin –Azee’ bid7 d0[ nihii 

naal kah haz1a gi t’11’1yis77 Baa hasti’ 

go hoo’a’ go N1bin 1ln4h7g77 tsx88[ go 

chii doo’i[ gi Bee Haz1anii Bee l3 doo 

go FDA da’7n77sh d00 kwii hazh0’0 

yin4[88h; N1bin bee’1l n4h7g77, 1n44lt’e’ 

choo’ih gi, h17’ 47 b7l1 k’eh dit’aah go 

N1bin &7 doo l77[ d00 N1bin 1ln44h gi 

bik’ih hw77 n44’ni’go bik’i’ 1d44st’77’

go’00lzin. N1bin nask11’g00 ts’7d1 bi

dziilgo id44[n7i doo d00 doo Baa’ayo 

hoolni da b44 h0z7n7 g77 naaltsos bee yah 

adoo’ n7[. FDA kw4’4 N1bin 1l n44h gi 

bee’ 1h0 doo n7[7g77 1lk44’ sinil go y1 

hasht’e di doo’ n77[, d00 ni b44 da’des

t1agonaaltsos bee naaz nil7g77 n7 da d7 

n0l 8[, bi n7y4 na’ad11go d00 bee 

Nahaz1anii bik’eh h0l98 gi da d7n00l 8[ 

go’ 7ndaN1bin 77l4h7g77 bich’8’ l3 doo.

2FDA Gh22j8’ naadiin naadiin yihah 

d33’ ts’7d1 b44 h0zin7 go Naaltsos 

bik’eh g00 ‘1’dool n77[ gi Dikos 

Ndtsaa’7 19 bi deezla’ biniy4 N1bin 

Tsx99[ go chii doo’i[ gi—Emergency

Use Authorization for Vaccines to 

Prevent COVID-19 woly40. B44 h0z7n7 

go‘ DikosNdts11’7 19 bi deezla’bi

N1bin 7g77 ‘1ln44h gi doo naakinil98 g00 

bi dziil go 7d 44[ n7i doo d00 b7’n44l 

22d7gi doo a[22’1daa t’4eda d00 doo 

baa’ayo hool nin da go chii doo’8[. &nda 

Taa’ g0ne’ na b0honit11h gi b44 h0z7n7 

go b0h0 n44 dz33 go choz 88d, b44 

h0zin7go id d44[ n77d d00 doo baa’ ayo 

hool nin go chi n11 n47 doo’i[ go b44 

h0zin. 

N1bin 1daal9 bi[ nahz11 g00 ‘a[ts4 

‘1kwiinaanish bi[ haz1n7gi B0h0n44dz3a 

go N1bin 1dool n7[ biniy4 naal kah. go 

n4l88h. N1bin 1lyaa d00 N1bin 1ln44hgi naaltsos 

d00 n1b0ho nest3’7gi d00 Naanish bi[ 

haz1a d00 yik’eh go’ 1da’iilaa h7g77 d00’ 

N1bin 1lyaah7g77 1b00 dzil go’ 7d44[n7n7 gi 

D77’ N1bin !niid7’ 1lyaa gi naal kah 

Investigational New Drug (IND) 

application doo gi Naaltsos bee s8’3 FDA 

bich’8’ 1l88h, t’ah doo b7la’ashdla’ii bee ni 

b0 ho ni tah da ha’niih. B7la’ashdla’ii’ 47 

doo bee ni b0 h0 nitaah FDA yee l3’a[eeh 

go’ 7nda. N1bin 1daalne’ gi t’11’ nab7honitaah go 

bee’ 22h3 hasinii d00 N1bin 7d44[n77 gi 

ni b44 da ho zin7g77 naaltsos bik11’ 

1daal ne’ go hool zhish. {a’ @2h3 hasin bi[ n7t’i’ j7 —Data Safety 

Monitoring Board yik’ih da deez99’ j7 tsin 

ne hesh j77’ bee w0j7i go da na h11z t3h 

11j7’ T11’ g0n4’4 haz3 N1bin ni b0 honi 

tah gi naanish bi[ haz32 di N1bin 1dool n7[ 

ho doo’niid33’ bee a[gha da’dees t’1a

nee’7sh t’11 bik’eh g00 ‘1da’ oh [aa d00 

FDA bi[ b44 h0zin kwii Dikos Ndtsaa’7 19

bi deezla’ bi N1bin b1. Naanish Bi[ haz1agi N1bin 1ln44h d00 

N1bin 1ln44hgi yii’ da hoo’9n7g77

N1t’33’ binaanish n7d47 n4l9 k’ad 

daats’7 FDA bi bee haz1anii bigha di 

N1bin B44’ d44 t’3 7d d44[ n77 gi d00 

doo baa’ayo hool nin da. FDA d0’ bi na hat’a’ t’11’ bii’ sil1 d00 

Naanish bi[ Haz1a d00 N1bin 1lyaa d00 

t’11 b7 hah goosh99 baa has ti’ go hoo’a’ 

go biniy4 naaltsos yah Ii doo ni[ N1bin

tsx99] go chii doo’i[ ha’n7igo koj8’ FDA 

bich’8’ k0l88h. N1bin 1ln44h gi yii’ da hoo’7n7g77 d00 

azee’ 22h 1dei[7n7 FDA’s Center for 

Biologics Evaluation and Research 

(CBER) Naaltsos FDA baa y7d t’aah 7g77 

t’0 baa hasti’ go hoo’a’ go tsx99[ go N1bin 

chii doo’ i[ ho doo’ n7id go 1n7[ tsoh j8’ 

na’ask1’7g77 b44 da h00 zin7g77 yinaj8’ n1 

n4l88h go 7nda FDA bich’8’ k0l88h 11j7 b22h 

sil1. FDA d00 Vaccines and Related Biological 

Products Advisory Committee (VRBPAC) 

1[ah n11 da’a[eeh d77 N1bin ni b0 honees 

t33’ gi Naaltsos a[h7 nii dee’7g77 b44 da 

hoozin7g77 n11nel 88h d00 baa y1ti’. 

B7n47; nil go da n7dinib22h7g77 naay7k’7h 

y1 n11 dasti’ go 7nda CBER y4ego bi

Naanish 1dayiilaah7g77 na b7k’7h 

y1daati’7g77 binaj8’ hazh0’0 yii’ n11 da 

d4st’99’ 22h3hasin gi, N1bin 7d44[77 gi d00 

1lyaa g77sh bee Nahaz1anii bik’eh go’ 

4’4lyaa nizh0n7 go b0h0n44 dz3ago Dikos 

Ndtsaa’7 bi deezla’ biN1bin h0l0 k’ad

Ashdladiin k4yah nih[ da s8’32n7g77 gi.

FDA b0h0l n77h n1bin 1l yaa h7g77 t’0 

baa hasti’ go hoo’a’ gi tsx99[ go chii 

doo’i[ ha’n77 go doo baa’ayo hool nin 

g00 d00 y’1’1t44h go’ id 44[ n7i go b0h0 

n44dz11 go’ alyaa bee hozin go, FDA 

yee l3’ a doo [e[ tsxi[ go chii doo’i[ gi.

FDA l3 n7igo koj8’ N1bin 77l4h7g77 t’11’ 1ko tsx7i[ go

N1bin FDA’s Center for Biologics Evaluation and 

Research (CBER) chii doo’i[ ha’n7n7 g77 bee l3’ 

n7igo be’el nih.